Welcome to our dedicated page for Klotho Neurosciences SEC filings (Ticker: KLTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing packed with gene-therapy data is tough. Klotho Neurosciences’ 10-K can run hundreds of pages on s-KL biology, clinical-trial endpoints and risk factors tied to neurodegenerative pipelines. Investors often Google “Klotho Neurosciences SEC filings explained simply” or “What is in the Klotho Neurosciences annual report 10-K simplified?” because the raw documents are dense. If you’ve ever searched for “Klotho Neurosciences insider trading Form 4 transactions” and ended up scrolling through EDGAR codes, you know the pain.
Stock Titan solves that problem. Our AI parses every 10-Q, 8-K, S-1 and proxy line by line, then surfaces plain-English summaries, key metrics and red-flag alerts. Real-time bots push “Klotho Neurosciences Form 4 insider transactions real-time” to your dashboard seconds after executives file. Want the “Klotho Neurosciences quarterly earnings report 10-Q filing” without combing through footnotes? We deliver side-by-side comparisons, highlight R&D spend on ALS and Alzheimer’s studies, and tag each section for quick navigation. It’s like understanding Klotho Neurosciences SEC documents with AI at your elbow.
Use these insights to monitor “Klotho Neurosciences executive stock transactions Form 4,” track burn-rate swings via “Klotho Neurosciences earnings report filing analysis,” or spot clinical milestones in “Klotho Neurosciences 8-K material events explained.” Curious about board pay? The “Klotho Neurosciences proxy statement executive compensation” is decoded to show option grants tied to s-KL milestones. From annual reports to surprise disclosures, every filing is updated the moment EDGAR posts—so biotech analysts, portfolio managers and industry watchers always get the full picture before making their next move.
Joseph Sinkule, who serves as Chief Executive Officer and a Director of Klotho Neurosciences, acquired 400,000 shares of the company's common stock on 09/25/2025. The filing states these shares were returned to him after he canceled a portion of a previously-reported non-recourse loan that had used the shares as collateral. After this transaction, Sinkule beneficially owns 4,846,700 shares, which the filing clarifies includes 1,000,000 shares issuable upon exercise of incentive options. The Form 4 is signed and dated 09/29/2025 and reports the change as a non-derivative acquisition by an executive who is also a director.
FAQ
What is the current stock price of Klotho Neurosciences (KLTO)?
What is the market cap of Klotho Neurosciences (KLTO)?
